# Comparing 123I-MIBG and 18F-MFBG Imaging in Patients With Newly Diagnosed, High Risk Neuroblastoma

> **NCT06858501** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Children's Oncology Group** · enrollment: 84 (estimated)

## Conditions studied

- Ganglioneuroblastoma
- Ganglioneuroblastoma, Nodular
- High Risk Neuroblastoma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **RADIATION:** Florbenguane F18
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** Positron Emission Tomography
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT06858501
- **Lead sponsor:** Children's Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-22
- **Primary completion:** 2028-12-20
- **Final completion:** 2028-12-20
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06858501

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06858501, "Comparing 123I-MIBG and 18F-MFBG Imaging in Patients With Newly Diagnosed, High Risk Neuroblastoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06858501. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*